Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: jake burns who wrote (610)	6/29/1998 7:57:00 AM
From: Emec	Respond to of 1510

Story on Bloomberg. Highlights: Researchers may have found a way to teach the immune system's toughest cells to better fight the virus that causes aids by stimulating them and exposing them to HIV proteins outside the body according to a study. Using samples from three infected patients, researchers at the University of Pittsburgh isolated key immune system cells and exposed them to HIV proteins and to Interleukin-12, a protein the body makes in response to infection. These cells then helped other immune cells to recognize and attack HIV-infected cells, the study said. No drugs have been approved yet for this purpose. Immune Response is considered the leader in this field. The Carlsbad California based company's drug Remune is in the later stages of testing required to file for U.S. Food and Drug Administration approval. Agouran Pharmaceutical Inc. which makes an HIV drug that rivals Merck's Crixivan, agreed to pay Immune Response Corp. as much as $77 million during the next 2 years as part of a development pact for Remune...